Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cedazuridine · Inqovi, E-7727

Small molecule · Inhibitor of cytidine deaminase (CDA) · developed by Taiho Pharmaceutical Co.

Approved FDA
1 Registered trials

What is Cedazuridine?

Cedazuridine is a cytidine deaminase inhibitor that binds and inhibits the enzyme CDA, which degrades cytidine analogs in the gastrointestinal tract and liver. Given with decitabine, it increases systemic decitabine exposure. It is combined with decitabine in INQOVI for myelodysplastic syndromes and acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Inqovi, E-7727
Drug type
Small molecule
Targets
cytidine deaminase (CDA)
Mechanism
Inhibitor of cytidine deaminase (CDA)
Pathways
cytidine degradation
Therapy area
Oncology
Developer
Taiho Pharmaceutical Co., Ltd.
In trials of
RIGL
FDA status
Approved as Inqovi, NDA212576 · FDA label
UNII
39IS23Q1EW

✅ FDA-approved uses

From the indications section of the FDA label (version of May 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06445959 Phase 1/2 Mutant IDH1 Inhibitor Olutasidenib Recruiting RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mutant IDH1 Inhibitor Olutasidenib

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.